Scailyte uniquely combines single-cell technologies with artificial intelligence to advance R&D and manufacturing processes and significantly reduce costs of Cell & Gene Therapies. Our proprietary AI platform ScaiVision™ links multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics) to pre-clinical or clinical CGT endpoints and identifies biomarkers for informed decisions throughout the process. This includes: 

  • Healthy donor and input cell population selection for the most potent cell therapy product 
  • Quality assessment, such as potency, durability, toxicity and heterogeneity of the product 
  • Predicting patient response for stratification in clinical trials 
  • Monitoring therapy recipients for informed patient management